The clinical-stage developer, focused on treatments for immune-mediated diseases, now anticipates net proceeds reaching approximately $265.1 million. Should underwriters exercise their option to purchase an additional 2.55 million shares, the total capital raised could climb to $305.4 million. This infusion of cash, combined with existing resources, provides the company with a financial runway extending into 2029.

Attovia has applied to list its stock on the Nasdaq Global Market under the ticker symbol ATTO. Following the offering, the company expects to have nearly 45.6 million shares outstanding, positioning its market capitalization at approximately $775 million based on the final $17-a-share valuation.